Queen Mary University of London (QMUL), in collaboration with Barts Health NHS Trust, has launched a groundbreaking global trial testing whether a six-monthly injection could replace daily blood pressure medication for patients with hypertension. The study represents what researchers describe as a "world first" approach to treating high blood pressure.
Global Trial Design and Scope
The three-year study involves 630 patients from across the world, with 100 participants recruited from the UK. The trial is funded by Alnylam Pharmaceuticals and supported by the National Institute for Health and Care Research (NIHR). Researchers are investigating whether subcutaneous injections administered twice yearly can effectively control blood pressure over prolonged periods.
Dr. Manish Saxena, study lead and deputy clinical director at QMUL, emphasized the collaborative nature of the research. "Solving health challenges on this scale cannot be achieved by one person or entity alone. We are thrilled to be working alongside Alnylam and combining our expertise to hopefully change modern medicine," she said.
Addressing a Significant Health Burden
According to NHS figures, approximately one-third of the adult population in the UK suffers from hypertension, with many unaware of their condition. The British Heart Foundation notes that while high blood pressure often presents no noticeable symptoms, untreated hypertension significantly increases the risk of heart attacks and strokes.
Currently, patients diagnosed with high blood pressure typically require daily tablet medication to regulate their condition. The British Heart Foundation explains that while there is not always a clear explanation for high blood pressure causes, most people develop it due to their diet, lifestyle, or underlying medical conditions.
Potential Clinical Benefits
The injection-based approach could address several challenges associated with current treatment protocols. Dr. Saxena outlined the potential advantages: "A twice-yearly treatment with injection underneath the skin would provide a better alternative to taking daily medication, which we believe would be welcome news for patients and make treating hypertension more convenient."
Professor Sir Nilesh Samani, medical director at the British Heart Foundation, highlighted the broader implications for patient care. "The study will determine whether an injection given twice a year lowers blood pressure sufficiently over a prolonged period. If this proves to be the case, it may provide an alternative to taking daily pills for some patients," he said.
Research Outlook
Dr. Saxena cautioned that the research is still in early stages but expressed optimism about the potential outcomes. "It is early days but our ultimate hope is that the treatment proves to be a safe and more manageable, practical solution to tackling high blood pressure," she noted.
The researchers are particularly focused on demonstrating both safety and efficacy of the novel treatment approach. If successful, the injection could represent a significant advancement in hypertension management, potentially improving patient compliance and quality of life for millions of people who currently rely on daily medication to manage their cardiovascular risk.
